A clinical trial led by Kirby Institute at UNSW Sydney has found that point-of-care testing for hepatitis B DNA is as effective as traditional laboratory testing, paving the way for faster diagnosis and treatment in hard-to-reach communities. The results have been published in the Journal of Clinical Microbiology.
Continue Reading this article here
